查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1967652

狂犬病兽用疫苗市场－全球产业规模、份额、趋势、机会、预测：按应用、分销管道、地区和竞争格局划分，2021-2031年

Rabies Veterinary Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球兽用狂犬病疫苗市场预计将从 2025 年的 6.1234 亿美元成长到 2031 年的 8.2435 亿美元，复合年增长率为 5.08%。

这些疫苗采用减毒活病毒疫苗、灭活疫苗或重组病毒株，作为生物免疫剂，可在家畜、伴侣动物和野生动物体内产生主动免疫力。推动疫苗市场成长的关键因素包括：旨在预防通用感染疾病传播的「同一健康」策略的日益普及，以及宠物人性化趋势的增强，这促使人们定期在预防性兽医护理方面投入资金。根据美国宠物用品协会 (APPA) 的报告，2023 年美国宠物产业的总支出达到 1,470 亿美元，这清楚地表明，饲主在动物福利方面的大量支出正在支撑疫苗需求。

市场概览
预测期 2027-2031
市场规模：2025年 6.1234亿美元
市场规模：2031年 8.2435亿美元
复合年增长率：2026-2031年 5.08%
成长最快的细分市场 野生动物
最大的市场 北美洲

儘管有这些成长要素，开发中国家市场在分销和仓储物流方面仍面临严峻挑战。虽然维持持续的低温运输至关重要，但在非洲和亚洲等高负担地区，基础设施的限制常常与此相衝突，导致疫苗劣化和取得受限。这些物流问题会严重阻碍有效的群体免疫接种工作，并限制市场渗透率。

市场驱动因素

全球宠物拥有率的上升以及人们对动物日益人性化的认知正在从根本上改变市场模式。随着饲主越来越将宠物视为家庭成员，对预防性生技药品和高品质兽医服务的需求也不断增长。这种文化转变促使人们更加严格地遵守疫苗接种计划，以确保伴侣动物的健康和长寿，从而导致新兴市场和已开发国家的年度疫苗接种剂量均显着增加。根据欧洲宠物产业协会（FEDIAF）于2024年6月发布的《2024年度报告》，欧洲宠物产业服务超过3.5亿隻宠物，显示预防性产品市场潜力巨大。此外，硕腾公司（Zoetis）报告称，其2024年伴侣动物产品收入达55.8亿美元，这充分体现了支撑市场持续成长的巨大经济价值。

第二个关键驱动力是基于「同一健康」理念的全球根除策略的扩展，该策略强调动物健康与人类健康之间的联繫，致力于根除犬源性狂犬病。国际组织和各国政府正在加强强制免疫接种，并增加对大规模免疫宣传活动的资金投入，以切断病毒传播源头。这些努力在通用感染疾病风险严重的地区至关重要，需要储备大量疫苗以用于公共卫生措施。例如，狂犬病防治组织Mission Rabies在2024年11月报告称，其团队在柬埔寨开展的为期两週的密集宣传活动中，成功为229,488隻犬隻接种了疫苗，这充分说明了这种协调行动的规模。这清楚地表明，有针对性的根除计划如何直接推动狂犬病疫苗的大规模分发和使用。

市场挑战

发展中国家的物流配送和仓储系统是全球兽用狂犬病疫苗市场成长的主要障碍。理论上，非洲和亚洲的狂犬病流行地区对疫苗的需求最高，但对不间断低温运输的严格要求却成为瓶颈，阻碍了生产商有效地服务这些地区。在交通基础设施落后、电力供应不稳定的地区，疫苗往往难以维持在所需的温度范围内，导致经销商遭受重大浪费和经济损失。因此，市场相关人员被迫将供应链限制在都市区，使得最需要疫苗的广大农村地区难以取得疫苗。

由于无法保证疫苗的有效性，大规模疫苗宣传活动的发展受到限制，进而阻碍了疫苗的大规模消费，直接导致市场规模萎缩。疫苗短缺与疾病负担沉重之间的差距，意味着该行业商业性机会的重大损失。根据世界卫生组织（世卫组织）2024年的数据，高达95%的人类狂犬病死亡病例发生在亚洲和非洲，这一统计数据凸显了这些地区缺乏有效的兽医应对方案，以及疫苗销售的巨大潜力尚未得到充分开发，因为这些地区的基础设施严重不足。

市场趋势

目前，市场正经历从传统灭活病毒製剂向mRNA疫苗和重组颗粒疫苗等先进平台技术的明显转型，这些技术具有更高的免疫抗原性和安全性。这项技术进步使得开发无佐剂製剂成为可能，透过精准的抗原编码诱导更强的免疫反应，同时消除注射部位肉瘤的风险。为了支持这项商业性转变，默克动物保健公司于2024年6月发布新闻稿，宣布其Nobivac NXT产品组合在加拿大成功上市，并推出了一种新型狂犬病疫苗。这是首个采用RNA颗粒技术的伴侣动物狂犬病疫苗系列。

同时，旨在控制野生动物族群中病毒携带者并建立免疫屏障以防止感染传播给家畜的口服狂犬病疫苗（ORV）策略的应用正在显着扩大。各国政府正在增加对大规模地面和空中投放狂犬病诱饵的资金投入，这些诱饵使用稳定的疫苗结构和新型引诱剂，即使在地形复杂的情况下，也能有效针对狐狸和浣熊等难以捕捉的媒介动物。例如，美国农业部（USDA）在2024年7月报告称，联邦机构已在东北部八个州分发了约330万个口服狂犬病诱饵（ONRAB），以评估群体免疫和分发方法的有效性，这便体现了这些根除工作的规模。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球兽用狂犬疫苗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依用途（伴侣动物、家畜、野生动物）
    • 分销管道（零售、电子商务、医​​院/诊所药房）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美兽用狂犬疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲兽用狂犬疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区兽用狂犬疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲兽用狂犬疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲兽用狂犬疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球兽用狂犬疫苗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Zoetis Inc.
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Virbac SA
  • Indian Immunologicals Ltd.
  • Ceva Sante Animale SA
  • Sanofi SA
  • Elanco Animal Health Inc.
  • BroadChem Philippines Biopharma Corporation
  • BiogenesisBago SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23983

The Global Rabies Veterinary Vaccines Market is projected to expand from USD 612.34 Million in 2025 to USD 824.35 Million by 2031, registering a CAGR of 5.08%. These vaccines, which utilize live-attenuated, inactivated, or recombinant viral strains, function as biological immunizing agents to generate active immunity in livestock, companion animals, and wildlife. Growth is largely propelled by the increasing adoption of "One Health" strategies aimed at stopping zoonotic transmission, alongside the rising trend of pet humanization that encourages regular spending on preventive veterinary health. As reported by the American Pet Products Association, total U.S. pet industry expenditures reached $147 billion in 2023, highlighting the significant financial investment owners make in animal welfare that sustains vaccine demand.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 612.34 Million
Market Size 2031USD 824.35 Million
CAGR 2026-20315.08%
Fastest Growing SegmentWildlife Animals
Largest MarketNorth America

Despite these growth factors, the market faces substantial hurdles related to distribution and storage logistics within developing countries. The strict necessity for maintaining a continuous cold chain frequently conflicts with infrastructure limitations in high-burden areas across Africa and Asia, resulting in vaccine spoilage and restricted access. These logistical failures can severely hamper effective mass immunization initiatives and limit market penetration.

Market Driver

The rising trends of global pet ownership and animal humanization are fundamentally altering the market landscape, as owners increasingly regard pets as essential family members, thereby boosting the demand for preventive biologicals and premium veterinary care. This cultural evolution fosters stricter adherence to vaccination schedules to guarantee the health and longevity of companion animals, drastically increasing the annual volume of doses administered in both emerging and developed economies. According to the 'Annual Report 2024' by FEDIAF in June 2024, the European pet industry caters to over 350 million pets, highlighting a massive addressable market for immunization products. Furthermore, Zoetis reported generating $5.58 billion in revenue from companion animal products in 2024, demonstrating the immense financial value supporting ongoing market growth.

A second pivotal driver is the expansion of 'One Health' global eradication strategies, which underscore the connection between animal and human health in the effort to eliminate dog-mediated rabies. International organizations and governments are increasingly enforcing vaccination mandates and financing mass immunization drives to cut off viral transmission at the source. These efforts are crucial in high-burden regions with acute zoonotic risks, requiring significant vaccine stockpiles for public health measures. Highlighting the magnitude of these coordinated actions, Mission Rabies reported in November 2024 that their teams successfully vaccinated 229,488 dogs in Cambodia during a two-week intensive campaign, showing how targeted eradication schemes directly drive the mass distribution and consumption of rabies vaccines.

Market Challenge

Distribution and storage logistics in developing nations constitute a significant obstacle to the growth of the global rabies veterinary vaccines market. Although the theoretical demand for immunization is highest in endemic areas within Africa and Asia, the stringent need for an unbroken cold chain creates a bottleneck that hinders manufacturers from effectively serving these regions. In locations suffering from poor transport infrastructure and unreliable electricity, keeping vaccines within the required temperature range is often unfeasible, leading to substantial spoilage rates and financial losses for distributors. As a result, market players are often forced to restrict supply chains to urban hubs, leaving vast rural populations-who need the product most-largely without access.

This inability to ensure product viability directly reduces market volume by limiting mass immunization campaigns that would otherwise generate large-scale vaccine consumption. The gap between low vaccine accessibility and high disease burden represents a major missed commercial opportunity for the industry. According to the World Health Organization in 2024, up to 95% of human rabies deaths occurred in Asia and Africa, a statistic that highlights the critical absence of effective veterinary control programs and the massive unrealized potential for vaccine sales in these markets lacking adequate infrastructure.

Market Trends

The market is undergoing a distinct transition toward advanced platform technologies, moving away from conventional inactivated virus formulations in favor of mRNA and recombinant particle vaccines that provide enhanced immunogenicity and safety. This technological progression enables the creation of adjuvant-free formulas that remove the risk of injection-site sarcomas while eliciting a stronger immune response through precise antigen coding. Confirming this commercial shift, Merck Animal Health announced in a June 2024 press release regarding 'New Rabies Vaccine Availability in Canada' that it had successfully launched the Nobivac NXT portfolio, marking the first veterinary rabies vaccine line for companion animals to employ RNA-particle technology.

Simultaneously, there is significant growth in the application of Oral Rabies Vaccination (ORV) strategies designed to control viral reservoirs in wildlife populations, thereby establishing immunological barriers against spillover into domestic animals. Governments are increasingly funding extensive ground and aerial baiting initiatives that use stable vaccine constructs and novel attractants to target elusive vector species, such as foxes and raccoons, in difficult terrains. To illustrate the scope of these abatement efforts, the U.S. Department of Agriculture (USDA) reported in July 2024 that federal agencies managed the distribution of roughly 3.3 million ONRAB oral vaccine baits across eight northeastern states to assess herd immunity efficacy and distribution methods.

Key Market Players

  • Zoetis Inc.
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Virbac S.A.
  • Indian Immunologicals Ltd.
  • Ceva Sante Animale S.A.
  • Sanofi S.A.
  • Elanco Animal Health Inc.
  • BroadChem Philippines Biopharma Corporation
  • BiogenesisBago S.A.

Report Scope

In this report, the Global Rabies Veterinary Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rabies Veterinary Vaccines Market, By Application

  • Companion Animals
  • Livestock Animals
  • Wildlife Animals

Rabies Veterinary Vaccines Market, By Distribution Channel

  • Retail
  • E-Commerce
  • Hospital/Clinic Pharmacies

Rabies Veterinary Vaccines Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rabies Veterinary Vaccines Market.

Available Customizations:

Global Rabies Veterinary Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rabies Veterinary Vaccines Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Companion Animals, Livestock Animals, Wildlife Animals)
    • 5.2.2. By Distribution Channel (Retail, E-Commerce, Hospital/Clinic Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Rabies Veterinary Vaccines Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rabies Veterinary Vaccines Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Rabies Veterinary Vaccines Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Rabies Veterinary Vaccines Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Distribution Channel

7. Europe Rabies Veterinary Vaccines Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Rabies Veterinary Vaccines Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Rabies Veterinary Vaccines Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Rabies Veterinary Vaccines Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Rabies Veterinary Vaccines Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Rabies Veterinary Vaccines Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Rabies Veterinary Vaccines Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Rabies Veterinary Vaccines Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Rabies Veterinary Vaccines Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Rabies Veterinary Vaccines Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Rabies Veterinary Vaccines Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Rabies Veterinary Vaccines Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Rabies Veterinary Vaccines Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Rabies Veterinary Vaccines Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Rabies Veterinary Vaccines Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Rabies Veterinary Vaccines Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Distribution Channel

10. South America Rabies Veterinary Vaccines Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rabies Veterinary Vaccines Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Rabies Veterinary Vaccines Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Rabies Veterinary Vaccines Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Rabies Veterinary Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. Merck & Co., Inc.
  • 15.4. Virbac S.A.
  • 15.5. Indian Immunologicals Ltd.
  • 15.6. Ceva Sante Animale S.A.
  • 15.7. Sanofi S.A.
  • 15.8. Elanco Animal Health Inc.
  • 15.9. BroadChem Philippines Biopharma Corporation
  • 15.10. BiogenesisBago S.A.

16. Strategic Recommendations

17. About Us & Disclaimer